Skip to main content
SHANGHAI SERUM BIO-TECHNOLOGY CO., LTD. logo

SHANGHAI SERUM BIO-TECHNOLOGY CO., LTD. — Investor Relations & Filings

Ticker · 688163 ISIN · CNE1000059X8 LEI · 8368001TREMN2G5DDS70 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 335 across all filing types
Latest filing 2022-02-24 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 688163

About SHANGHAI SERUM BIO-TECHNOLOGY CO., LTD.

https://www.serum-china.com.cn/en/

Shanghai Serum Bio-Technology Co., Ltd. is a specialized biopharmaceutical enterprise focused on the research, development, and manufacturing of therapeutic biological products. The company primarily produces a range of antiserums and antitoxins, including specialized antivenoms for various snake species, tetanus antitoxins, and rabies immunoglobulins. Its product portfolio supports emergency medical care and infectious disease management. The organization maintains advanced production facilities compliant with Good Manufacturing Practice (GMP) standards to ensure the safety and efficacy of its biological treatments. By leveraging biotechnological innovation, the company serves clinical needs in healthcare sectors, providing critical life-saving interventions for envenomation and acute bacterial toxins.

Recent filings

Filing Released Lang Actions
赛伦生物首次公开发行股票并在科创板上市投资风险特别公告
Capital/Financing Update Classification · 95% confidence The document is titled as an "Investment Risk Special Announcement" related to the initial public offering (IPO) and listing of Shanghai Sailun Biotechnology Co., Ltd. on the STAR Market (科创板). It details the issuance of new shares, pricing, subscription procedures, investor warnings, and regulatory approvals. The content focuses on the IPO process, pricing, allocation, and associated investment risks rather than presenting financial statements or earnings data. It is not a full financial report like an Annual Report (10-K) or Interim Report (IR), nor is it a simple announcement of a report publication. The document is a detailed announcement related to capital raising and financing activities for the IPO. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (7489 characters) and detailed content support this classification with high confidence.
2022-02-24 Chinese
赛伦生物首次公开发行股票并在科创板上市网上路演公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the initial public offering (IPO) of Shanghai Sairen Biotechnology Co., Ltd. on the STAR Market (科创板). It details the issuance of new shares, the allocation method (strategic placement, offline and online issuance), and the schedule for an online roadshow to present the offering to investors. The document includes no financial statements or detailed financial analysis but serves to inform investors about the IPO process and the upcoming investor presentation event. The document length is short (1357 characters), and it is clearly an announcement of an event related to capital raising rather than the actual financial report or prospectus. Therefore, it fits best under Capital/Financing Update (CAP).
2022-02-23 Chinese
赛伦生物首次公开发行股票并在科创板上市发行安排及初步询价公告
Capital/Financing Update Classification · 100% confidence The document is a detailed announcement regarding the initial public offering (IPO) of Shanghai Sairen Biotechnology Co., Ltd. on the STAR Market (科创板) of the Shanghai Stock Exchange. It includes extensive information about the issuance arrangement, preliminary inquiry, strategic placement, pricing, investor qualifications, subscription limits, lock-up periods, and timelines related to the IPO process. The document references regulatory approvals from the China Securities Regulatory Commission (CSRC) and Shanghai Stock Exchange rules, and it is clearly an official issuance and offering announcement. It is not a financial report, earnings release, or management discussion, nor is it a voting result or a board change announcement. It is also not a report publication announcement since it contains substantive details about the offering itself. The content fits best into the category of Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities such as IPOs and share issuance.
2022-02-17 Chinese
赛伦生物首次公开发行股票并在科创板上市招股意向书附录
Capital/Financing Update Classification · 95% confidence The document is titled as an application file for the initial public offering (IPO) and listing on the STAR Market (科创板) by Shanghai Serum Bio-Technology Co., Ltd. It includes sections such as the issuance sponsorship letter, financial statements and audit reports, internal control verification report, legal opinions, and other related documents. The text contains detailed descriptions of the underwriting and sponsorship process, compliance with laws and regulations, risk disclosures, and financial data audited by certified accountants. The document is comprehensive, over 15,000 characters, and contains substantive financial and operational information related to the IPO process. This type of document is a formal filing related to a company's initial public offering and listing, which is typically classified as a Capital/Financing Update (CAP) because it concerns the issuance of new shares and listing on a stock exchange. It is not an annual report, audit report alone, or earnings release, but a detailed IPO prospectus and related sponsorship documents. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2022-02-17 Chinese
赛伦生物首次公开发行股票并在科创板上市招股意向书
Regulatory Filings Classification · 95% confidence The document is a detailed prospectus (招股意向书) for an initial public offering (IPO) on the Shanghai Stock Exchange's STAR Market (科创板). It includes extensive information about the company's business, financial data, risk factors, governance, and audit reports. The document is lengthy (15,000 characters) and contains substantive financial data, business descriptions, risk disclosures, and audit opinions. This type of document is characteristic of an IPO prospectus or registration statement, which is a regulatory filing but does not fit neatly into categories like Annual Report (10-K) or Interim Report (IR). It is not a simple announcement or a brief summary but a comprehensive regulatory filing related to the company's public offering. Given the definitions, the best fit is Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory documents that do not fit other specific categories.
2022-02-17 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.